Published in Cancer Weekly, November 15th, 2005
For the third quarter of 2005, total revenues were $67.9 million compared to $55.6 million in the third quarter of 2004. Product sales increased to $66.4 million in the third quarter of 2005 from $54.9 million in the third quarter of 2004, primarily due to increased sales of Aloxi (palonosetron hydrochloride) injection. U.S. sales of Aloxi injection totaled $63.6 million, compared to $47.6 million in the third quarter of 2004.
Total costs and expenses decreased to $54.9 million in the third quarter of 2005...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.